Isofol Medical Logo

Isofol Medical

ISIN: SE0009581051 | Ticker: ISOFOL | LEI: 549300MCXYAHG7VBHX75
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Isofol Medical

Company Description

Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer.

Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.

Vision:
“Isofol will help extend life and improve the quality of life for cancer patients”

Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.

Year founded

2008

Headquarters

Arvid Wallgrens Backe 20, 41346 Gothenburg – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 148,130,000.00 401,363,000.00 213,464,000.00
Noncurrent Assets N/A 8,289,000.00 6,755,000.00 4,013,000.00
Property Plant And Equipment N/A 3,258,000.00 1,745,000.00 4,013,000.00
Other Property Plant And Equipment N/A N/A 1,745,000.00 4,013,000.00
Intangible Assets Other Than Goodwill N/A 0.00 0.00 0.00
Other Noncurrent Financial Assets N/A 5,031,000.00 5,009,000.00 0.00
Current Assets N/A 139,841,000.00 394,609,000.00 209,451,000.00
Trade And Other Current Receivables N/A 2,318,000.00 0.00 0.00
Current Prepaid Expenses N/A 12,390,000.00 2,884,000.00 1,215,000.00
Cash and cash equivalents 126,983,000.00 116,393,000.00 379,448,000.00 190,583,000.00
Equity And Liabilities N/A 148,130,000.00 401,363,000.00 213,464,000.00
Equity 104,908,000.00 66,567,000.00 318,233,000.00 158,479,000.00
Issued Capital N/A 2,552,000.00 4,945,000.00 4,945,000.00
Retained Earnings N/A -515,077,000.00 -704,069,000.00 -904,319,000.00
Additional Paidin Capital N/A 768,083,000.00 1,217,607,000.00 1,217,607,000.00
Liabilities N/A 81,563,000.00 83,130,000.00 54,985,000.00
Noncurrent Liabilities N/A 1,439,000.00 110,000.00 3,250,000.00
Current Liabilities N/A 80,124,000.00 83,020,000.00 51,735,000.00
Trade And Other Current Payables N/A 20,889,000.00 17,736,000.00 7,520,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 37,119,000.00 22,407,000.00 12,797,000.00
Other Income 18,000.00 0.00 59,000.00
Employee Benefits Expense 22,740,000.00 27,721,000.00 34,748,000.00
Depreciation And Amortisation Expense 1,770,000.00 1,596,000.00 1,642,000.00
Other Expense By Nature 199,535,000.00 196,712,000.00 142,114,000.00
Other Gains Losses 413,000.00 -843,000.00 -1,812,000.00
Profit Loss From Operating Activities -186,494,000.00 -204,465,000.00 -167,460,000.00
Finance Income 4,000.00 4,383,000.00 7,750,000.00
Finance Costs 2,501,000.00 168,000.00 44,000.00
Profit Loss Before Tax -188,991,000.00 -200,251,000.00 -159,755,000.00
Income Tax Expense Continuing Operations 1,000.00 0.00 0.00
Profit (loss) -188,992,000.00 -200,251,000.00 -159,755,000.00
Profit Loss Attributable To Owners Of Parent -188,992,000.00 -200,251,000.00 -159,755,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -188,992,000.00 -200,251,000.00 -159,755,000.00
Adjustments For Decrease Increase In Other Operating Receivables N/A -14,050,000.00 9,860,000.00 -504,000.00
Adjustments For Increase Decrease In Other Operating Payables N/A 38,813,000.00 4,907,000.00 -31,166,000.00
Other Adjustments For Noncash Items N/A 3,958,000.00 -2,946,000.00 450,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 1,000.00 0.00 0.00
Cash Flows From Used In Operating Activities N/A -160,270,000.00 -188,429,000.00 -190,975,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 0.00 0.00
Cash Flows From Used In Investing Activities N/A 0.00 0.00 0.00
Proceeds From Issuing Shares N/A 151,258,000.00 451,917,000.00 0.00
Proceeds From Issuing Other Equity Instruments N/A 308,000.00 108,000.00 23,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,553,000.00 1,548,000.00 1,704,000.00
Cash Flows From Used In Financing Activities N/A 150,013,000.00 450,477,000.00 -1,681,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -10,257,000.00 262,048,000.00 -192,656,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -334,000.00 1,007,000.00 3,791,000.00
Cash and cash equivalents 126,983,000.00 116,393,000.00 379,448,000.00 190,583,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.01.24 Magnus Hurst Other Buy SEK 24,150.00
12.09.22 AB Windar Other Buy SEK 305,000.00
09.12.21 Tony Gustavsson Other Sell SEK 858.00
09.12.21 Tony Gustavsson Other Sell SEK 152.79
14.06.21 HealthCom GmbH Other Buy SEK 1,493,350.40
10.06.21 Gustaf Albèrt Other Other SEK 96,979.20
23.11.20 Tony Gustavsson Other Buy SEK 43,487.58
23.11.20 Tony Gustavsson Other Buy SEK 29,971.17
16.11.20 Sven Eriksson Other Sell SEK 43,487.58
16.11.20 Sven Eriksson Other Sell SEK 29,971.17

Capital markets information

ISIN

SE0009581051

LEI

549300MCXYAHG7VBHX75

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.